Enanta Pharmaceuticals Stock News

Tarrytown, New York, Dec. 03, 2021 (GLOBE NEWSWIRE) -- The demand for high-quality specialty medical care has never been higher, and it continues to grow. To be able to evolve and keep pace with this growing demand, ENT and Allergy Associates, LLP, the preeminent Ear, Nose, Throat, Allergy, and Audiology practice in the region, is proud to announce that Michael S. Goldrich, M.D., FACS, will be joining its Somerset, NJ clinical office, effective January 1, 2022. Dr. Goldrich has practiced in the Central New Jersey area for over 20 years and comes to ENTA as a highly recognized physician. He will practice alongside Otolaryngologists Bruce Edelman, M.D., and Steven Sabin, M.D., as well as Allergist / Immunologist Stacey Galowitz, D.O. ENTA''s Somerset office includes six ENT exam rooms, an Audiology booth, a hearing aid dispensing room, an Allergy suite including dedicated Allergy exam rooms, a spacious reception area, full-service electronic health records, and many other cutting-edge conveniences.

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) traded down 7.1% during trading on Monday . The company traded as low as $85.25 and last traded at $85.32. 7,674 shares traded hands during trading, a decline of 95% from the average session volume of 153,333 shares. The stock had previously closed at $91.89. A number of research analysts have []

ENT and Allergy Associates LLP (ENTA), based in Tarrytown, provides ear, nose, throat and allergy care throughout New York and New Jersey and continues to add to its staff. Rutgers-trained otolaryngologist Aron Kandinov, M.D., will join the groups Williamsburg, Brooklyn, office and Ankit Kansal, M.D., will join the Astoria, New York, office. Kandinov who will [] The post ENTA CONTINUES TO EXPAND appeared first on Westfair Communications .

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)s stock price traded down 7.1% during mid-day trading on Monday . The company traded as low as $85.25 and last traded at $85.32. 7,674 shares were traded during trading, a decline of 95% from the average session volume of 153,333 shares. The stock had previously closed at $91.89. A number of []

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target lifted by Oppenheimer from $55.00 to $73.00 in a research note issued to investors on Wednesday morning, The Fly reports. They currently have a market perform rating on the biotechnology companys stock. ENTA has been the topic of several other reports. SVB Leerink decreased their target price on [] The post Oppenheimer Increases Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $73.00 appeared first on ETF Daily News .

Enanta Pharmaceuticals Inc (ENTA) shares closed this week 22.0% higher than it did at the end of last week. The stock is currently up 118.3% year-to-date, up 114.0% over the past 12 months, and up 181.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Shares traded as high as $92.90 and as low as $73.71 this week.Shares closed 9.9% below its 52-week high and 127.9% above its 52-week low.Trading volume this week was 29.0% lower than the 10-day average and 12.0% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -3894.2% The company's stock price performance over the past 12 months beats the peer average by 14159.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

During the last session, Enanta Pharmaceuticals Inc. (NASDAQ:ENTA)s traded shares were 0.35 million, with the beta value of the company hitting 0.59. At the end of the trading day, the stocks price was $91.89, reflecting an intraday gain of 5.75% or $5.0. The 52-week high for the ENTA share is $102.00, that puts it down Can You Get A Quick Recovery From Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) Given A -11.0% drop From High? Read More »

Invesco Ltd. lessened its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 13.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 281,164 shares of the biotechnology companys stock after selling 44,392 shares during the quarter. Invesco Ltd. owned approximately 1.39% of Enanta Pharmaceuticals worth []

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target cut by SVB Leerink from $92.00 to $85.00 in a research report report published on Tuesday, The Fly reports. They currently have a market perform rating on the biotechnology companys stock. SVB Leerink also issued estimates for Enanta Pharmaceuticals FY2022 earnings at ($3.45) EPS, FY2023 earnings at ($4.80) []

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Investment analysts at Piper Sandler reduced their Q1 2022 earnings per share estimates for shares of Enanta Pharmaceuticals in a research note issued on Monday, November 22nd. Piper Sandler analyst Y. Rahimi now anticipates that the biotechnology company will post earnings per share of ($1.21) for the quarter, down from []

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target upped by JMP Securities from $111.00 to $116.00 in a research report sent to investors on Tuesday, The Fly reports. They currently have an outperform rating on the biotechnology companys stock. A number of other research analysts have also commented on ENTA. Robert W. Baird upped their price []

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Investment analysts at Piper Sandler decreased their FY2025 earnings per share (EPS) estimates for Enanta Pharmaceuticals in a research report issued on Monday, November 22nd. Piper Sandler analyst Y. Rahimi now anticipates that the biotechnology company will post earnings per share of $25.29 for the year, down from their prior []

Enanta Pharmaceuticals (NASDAQ:ENTA) had its target price upped by Oppenheimer from $55.00 to $73.00 in a research report released on Wednesday morning, The Fly reports. The firm currently has a market perform rating on the biotechnology companys stock. A number of other analysts have also weighed in on the stock. JMP Securities increased their price []

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Investment analysts at Piper Sandler dropped their FY2025 earnings per share estimates for Enanta Pharmaceuticals in a report released on Monday, November 22nd. Piper Sandler analyst Y. Rahimi now expects that the biotechnology company will post earnings of $25.29 per share for the year, down from their previous forecast of []